

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

RTSP-0160

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/913684

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/US00/00654

11 January 2000

23 February 1999

TITLE OF INVENTION

Antisense Modulation of SMAD2 Expression

APPLICANT(S) FOR DO/EO/US

MONIA, Brett P. et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with
20. ☐ A second copy of the published international application under 35 U
21. ☐ A second copy of the English language translation of the internation
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

"Express Mail" Label No. **EL750774529US**
Date of Deposit **August 16, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

1) Courtesy copy of International Application

2) Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825 and amended sequence list

3) Copy of Written Opinion

4) Return post card


U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 077/913084		INTERNATIONAL APPLICATION NO PCT/US00/00654		ATTORNEY'S DOCKET NUMBER RTSP-0160	
--	--	---	--	--	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	19 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$430.00	
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$430.00	
Applicant, ISIS Pharmaceuticals, Inc. is entitled to small entity status. It is a small business concern.				Amount to be: refunded \$ charged \$	

a. <input checked="" type="checkbox"/> A check in the amount of \$430.00 to cover the above fees is enclosed.	
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.	
c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.	
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257 Kathleen A. Tyrrell, Reg. No. 38,350 Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 Telephone: (856) 810-1515 Facsimile : (856) 810-1454	<div style="text-align: center;">  SIGNATURE </div> <hr/> <div style="text-align: center;"> Kathleen A. Tyrrell NAME </div> <hr/> <div style="text-align: center;"> 38,350 REGISTRATION NUMBER </div> <hr/> <div style="text-align: center;"> August 16, 2001 DATE </div>
---	--

09/913684

531 Rec'd PCT 16 AUG 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0160
Inventors: Monia and Cowsert
Serial No.: Not yet assigned
Filing Date: Herewith
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: Antisense Modulation of SMAD2 Expression

"Express Mail" Label No. EL 750774529 US
Date of Deposit - August 16, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

It is respectfully requested that the Sequence Listing of the instant specification be deleted and replaced with the amended Sequence Listing provided herewith. A paper copy and a CRF copy of the amended Sequence Listing are provided herewith.

The replacement Sequence Listing has been amended to conform with the current Sequence Listing Rules. However, data presented in the Sequence Listing is identical to that originally filed.

Thus, no new matter has been added by this amendment.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: August 16, 2001

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

PCT09

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/913,684

TIME: 09:34:05

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

ENTERED

```

3 <110> APPLICANT: Brett P. Monia
4      Lex M. Cowsert
5      ISIS PHARMACEUTICALS, INC.
7 <120> TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD2 EXPRESSION
9 <130> FILE REFERENCE: RTSP-0160
C--> 11 <140> CURRENT APPLICATION NUMBER: US/09/913,684
C--> 12 <141> CURRENT FILING DATE: 2001-08-16
14 <150> PRIOR APPLICATION NUMBER: US 09/255,912
15 <151> PRIOR FILING DATE: 1999-02-23
17 <160> NUMBER OF SEQ ID NOS: 47
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 1710
21 <212> TYPE: DNA
22 <213> ORGANISM: Homo sapiens
24 <220> FEATURE:
25 <221> NAME/KEY: CDS
26 <222> LOCATION: (107)..(1510)
28 <400> SEQUENCE: 1
29 ccgcgcgcgcgc ggagaagcag ctgcgcgcgc agcagccgcgc cagccgcgcgc gaggttcgat      60
31 acaagaggct gttttcctag cgtggcttgc tgcctttggt aagaac atg tcg tcc      115
32                                     Met Ser Ser
33                                     1
35 atc ttg cca ttc acg ccg cca gtt gtg aag aga ctg ctg gga tgg aag      163
36 Ile Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu Gly Trp Lys
37      5              10              15
39 aag tca gct ggt ggg tct gga gga gca ggc gga gag cag aat ggg      211
40 Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu Gln Asn Gly
41 20              25              30              35
43 cag gaa gaa aag tgg tgt gag aaa gca gtg aaa agt ctg gtg aag aag      259
44 Gln Glu Glu Lys Trp Cys Glu Lys Ala Val Lys Ser Leu Val Lys Lys
45      40              45              50
47 cta aag aaa aca gga cga tta gat gag ctt gag aaa gcc atc acc act      307
48 Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala Ile Thr Thr
49      55              60              65
51 caa aac tgt aat act aaa tgt gtt acc ata cca agc act tgc tct gaa      355
52 Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr Cys Ser Glu
53      70              75              80
55 att tgg gga ctg agt aca cca aat acg ata gat cag tgg gat aca aca      403
56 Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp Asp Thr Thr
57      85              90              95
59 ggc ctt tac agc ttc tct gaa caa acc agg tct ctt gat ggt cgt ctc      451
60 Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp Gly Arg Leu
61 100              105              110              115
63 cag gta tcc cat cga aaa gga ttg cca cat gtt ata tat tgc cga tta      499
64 Gln Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr Cys Arg Leu
65      120              125              130
67 tgg cgc tgg cct gat ctt cac agt cat cat gaa ctc aag gca att gaa      547

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/913,684

DATE: 08/30/2001

TIME: 09:34:05

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

68	Trp	Arg	Trp	Pro	Asp	Leu	His	Ser	His	His	Glu	Leu	Lys	Ala	Ile	Glu	
69				135					140					145			
71	aac	tgc	gaa	tat	gct	ttt	aat	ctt	aaa	aag	gat	gaa	gta	tgt	gta	aac	595
72	Asn	Cys	Glu	Tyr	Ala	Phe	Asn	Leu	Lys	Lys	Asp	Glu	Val	Cys	Val	Asn	
73			150					155					160				
75	cct	tac	cac	tat	cag	aga	gtt	gag	aca	cca	gtt	ttg	cct	cca	gta	tta	643
76	Pro	Tyr	His	Tyr	Gln	Arg	Val	Glu	Thr	Pro	Val	Leu	Pro	Pro	Val	Leu	
77		165					170				175						
79	gtg	ccc	cga	cac	acc	gag	atc	cta	aca	gaa	ctt	ccg	cct	ctg	gat	gac	691
80	Val	Pro	Arg	His	Thr	Glu	Ile	Leu	Thr	Glu	Leu	Pro	Pro	Leu	Asp	Asp	
81	180					185					190				195		
83	tat	act	cac	tcc	att	cca	gaa	aac	act	aac	ttc	cca	gca	gga	att	gag	739
84	Tyr	Thr	His	Ser	Ile	Pro	Glu	Asn	Thr	Asn	Phe	Pro	Ala	Gly	Ile	Glu	
85				200					205					210			
87	cca	cag	agt	aat	tat	att	cca	gaa	acg	cca	cct	cct	gga	tat	atc	agt	787
88	Pro	Gln	Ser	Asn	Tyr	Ile	Pro	Glu	Thr	Pro	Pro	Pro	Gly	Tyr	Ile	Ser	
89			215						220				225				
91	gaa	gat	gga	gaa	aca	agt	gac	caa	cag	ttg	aat	caa	agt	atg	gac	aca	835
92	Glu	Asp	Gly	Glu	Thr	Ser	Asp	Gln	Gln	Leu	Asn	Gln	Ser	Met	Asp	Thr	
93			230				235					240					
95	ggc	tct	cca	gca	gaa	cta	tct	cct	act	act	ctt	tcc	cct	gtt	aat	cat	883
96	Gly	Ser	Pro	Ala	Glu	Leu	Ser	Pro	Thr	Thr	Leu	Ser	Pro	Val	Asn	His	
97		245				250					255						
99	agc	ttg	gat	tta	cag	cca	gtt	act	tac	tca	gaa	cct	gca	ttt	tgg	tgt	931
100	Ser	Leu	Asp	Leu	Gln	Pro	Val	Thr	Tyr	Ser	Glu	Pro	Ala	Phe	Trp	Cys	
101	260				265						270				275		
103	tca	ata	gca	tat	tat	gaa	tta	aat	cag	agg	gtt	gga	gaa	acc	ttc	cat	979
104	Ser	Ile	Ala	Tyr	Tyr	Glu	Leu	Asn	Gln	Arg	Val	Gly	Glu	Thr	Phe	His	
105				280					285				290				
107	gca	tca	cag	ccc	tca	ctc	act	gta	gat	ggc	ttt	aca	gac	cca	tca	aat	1027
108	Ala	Ser	Gln	Pro	Ser	Leu	Thr	Val	Asp	Gly	Phe	Thr	Asp	Pro	Ser	Asn	
109			295					300				305					
111	tca	gag	agg	ttc	tgc	tta	ggt	tta	ctc	tcc	aat	gtt	aac	cga	aat	gcc	1075
112	Ser	Glu	Arg	Phe	Cys	Leu	Gly	Leu	Ser	Asn	Val	Asn	Arg	Asn	Ala		
113		310				315					320						
115	acg	gta	gaa	atg	aca	aga	agg	cat	ata	gga	aga	gga	gtg	cgc	tta	tac	1123
116	Thr	Val	Glu	Met	Thr	Arg	Arg	His	Ile	Gly	Arg	Gly	Val	Arg	Leu	Tyr	
117		325				330					335						
119	tac	ata	ggt	ggg	gaa	gtt	ttt	gct	gag	tgc	cta	agt	gat	agt	gca	atc	1171
120	Tyr	Ile	Gly	Gly	Glu	Val	Phe	Ala	Glu	Cys	Leu	Ser	Asp	Ser	Ala	Ile	
121	340				345				350				355				
123	ttt	gtg	cag	agc	ccc	aat	tgt	aat	cag	aga	tat	ggc	tgg	cac	cct	gca	1219
124	Phe	Val	Gln	Ser	Pro	Asn	Cys	Asn	Gln	Arg	Tyr	Gly	Trp	His	Pro	Ala	
125			360					365				370					
127	aca	gtg	tgt	aaa	att	cca	cca	ggc	tgt	aat	ctg	aag	atc	ttc	aac	aac	1267
128	Thr	Val	Cys	Lys	Ile	Pro	Pro	Gly	Cys	Asn	Leu	Lys	Ile	Phe	Asn	Asn	
129			375					380				385					
131	cag	gaa	ttt	gct	gct	ctt	ctg	gct	cag	tct	gtt	aat	cag	ggt	ttt	gaa	1315
132	Gln	Glu	Phe	Ala	Ala	Leu	Leu	Ala	Gln	Ser	Val	Asn	Gln	Gly	Phe	Glu	

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/913,684

DATE: 08/30/2001

TIME: 09:34:05

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

```

133          390          395          400
135 gcc gtc tat cag cta act aga atg tgc acc ata aga atg agt ttt gtg      1363
136 Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Ile Arg Met Ser Phe Val
137      405          410          415
139 aaa ggg tgg gga gca gaa tac cga agg cag acg gta aca agt act cct      1411
140 Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Thr Val Thr Ser Thr Pro
141 420          425          430          435
143 tgc tgg att gaa ctt cat ctg aat gga cct cta cag tgg ttg gac aaa      1459
144 Cys Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp Leu Asp Lys
145          440          445          450
147 gta tta act cag atg gga tcc cct tca gtg cgt tgc tca agc atg tca      1507
148 Val Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser Ser Met Ser
149          455          460          465
151 taa agcttcacca atcaagtccc atgaaaagac ttaatgtaac aactcttctg      1560
153 tcatagcatt gtgtgtggtc cctatggact gtttactatc caaaagttca agagagaaaa      1620
155 cagcacttga ggtctcatca attaaagcac cttgtggaat ctgtttccta tatttgaata      1680
157 ttagatggga aaattagtgt cataaagatc      1710
160 <210> SEQ ID NO: 2
161 <211> LENGTH: 20
162 <212> TYPE: DNA
163 <213> ORGANISM: Artificial Sequence
165 <220> FEATURE:
166 <223> OTHER INFORMATION: PCR Primer
168 <400> SEQUENCE: 2
169 ggcttgctgc ctttggttaag      20
172 <210> SEQ ID NO: 3
173 <211> LENGTH: 21
174 <212> TYPE: DNA
175 <213> ORGANISM: Artificial Sequence
177 <220> FEATURE:
178 <223> OTHER INFORMATION: PCR Primer
180 <400> SEQUENCE: 3
181 tccatcccag cagtctcttc a      21
184 <210> SEQ ID NO: 4
185 <211> LENGTH: 25
186 <212> TYPE: DNA
187 <213> ORGANISM: Artificial Sequence
189 <220> FEATURE:
190 <223> OTHER INFORMATION: PCR Probe
192 <400> SEQUENCE: 4
193 catgtcgtcc atcttgccat tcacg      25
196 <210> SEQ ID NO: 5
197 <211> LENGTH: 19
198 <212> TYPE: DNA
199 <213> ORGANISM: Artificial Sequence
201 <220> FEATURE:
202 <223> OTHER INFORMATION: PCR Primer
204 <400> SEQUENCE: 5
205 gaaggtgaag gtcggagtc      19

```

RAW SEQUENCE LISTING

DATE: 08/30/2001

PATENT APPLICATION: US/09/913,684

TIME: 09:34:05

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

```

208 <210> SEQ ID NO: 6
209 <211> LENGTH: 20
210 <212> TYPE: DNA
211 <213> ORGANISM: Artificial Sequence
213 <220> FEATURE:
214 <223> OTHER INFORMATION: PCR Primer
216 <400> SEQUENCE: 6
217 gaagatggtg atgggatttc                20
220 <210> SEQ ID NO: 7
221 <211> LENGTH: 20
222 <212> TYPE: DNA
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: PCR Probe
228 <400> SEQUENCE: 7
229 caagcttccc gttctcagcc                20
232 <210> SEQ ID NO: 8
233 <211> LENGTH: 18
234 <212> TYPE: DNA
235 <213> ORGANISM: Artificial Sequence
237 <220> FEATURE:
238 <223> OTHER INFORMATION: Antisense Oligonucleotide
240 <400> SEQUENCE: 8
241 agctgcttct ccgccgcc                18
244 <210> SEQ ID NO: 9
245 <211> LENGTH: 18
246 <212> TYPE: DNA
247 <213> ORGANISM: Artificial Sequence
249 <220> FEATURE:
250 <223> OTHER INFORMATION: Antisense Oligonucleotide
252 <400> SEQUENCE: 9
253 aaacagcctc ttgtatcg                18
256 <210> SEQ ID NO: 10
257 <211> LENGTH: 18
258 <212> TYPE: DNA
259 <213> ORGANISM: Artificial Sequence
261 <220> FEATURE:
262 <223> OTHER INFORMATION: Antisense Oligonucleotide
264 <400> SEQUENCE: 10
265 cgtgaatggc aagatgga                18
268 <210> SEQ ID NO: 11
269 <211> LENGTH: 18
270 <212> TYPE: DNA
271 <213> ORGANISM: Artificial Sequence
273 <220> FEATURE:
274 <223> OTHER INFORMATION: Antisense Oligonucleotide
276 <400> SEQUENCE: 11
277 ctcttcacaa ctggcggc                18
280 <210> SEQ ID NO: 12

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/913,684

DATE: 08/30/2001

TIME: 09:34:05

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

```

281 <211> LENGTH: 18
282 <212> TYPE: DNA
283 <213> ORGANISM: Artificial Sequence
285 <220> FEATURE:
286 <223> OTHER INFORMATION: Antisense Oligonucleotide
288 <400> SEQUENCE: 12
289 cttccatccc agcagtct 18
292 <210> SEQ ID NO: 13
293 <211> LENGTH: 18
294 <212> TYPE: DNA
295 <213> ORGANISM: Artificial Sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Antisense Oligonucleotide
300 <400> SEQUENCE: 13
301 tgctcctcca gacccacc 18
304 <210> SEQ ID NO: 14
305 <211> LENGTH: 18
306 <212> TYPE: DNA
307 <213> ORGANISM: Artificial Sequence
309 <220> FEATURE:
310 <223> OTHER INFORMATION: Antisense Oligonucleotide
312 <400> SEQUENCE: 14
313 ctctcctccg cctgctcc 18
316 <210> SEQ ID NO: 15
317 <211> LENGTH: 18
318 <212> TYPE: DNA
319 <213> ORGANISM: Artificial Sequence
321 <220> FEATURE:
322 <223> OTHER INFORMATION: Antisense Oligonucleotide
324 <400> SEQUENCE: 15
325 ttccctgcca ttctgctc 18
328 <210> SEQ ID NO: 16
329 <211> LENGTH: 18
330 <212> TYPE: DNA
331 <213> ORGANISM: Artificial Sequence
333 <220> FEATURE:
334 <223> OTHER INFORMATION: Antisense Oligonucleotide
336 <400> SEQUENCE: 16
337 ctcacaccac ttttcttc 18
340 <210> SEQ ID NO: 17
341 <211> LENGTH: 18
342 <212> TYPE: DNA
343 <213> ORGANISM: Artificial Sequence
345 <220> FEATURE:
346 <223> OTHER INFORMATION: Antisense Oligonucleotide
348 <400> SEQUENCE: 17
349 tcactgcttt ctacacacc 18
352 <210> SEQ ID NO: 18
353 <211> LENGTH: 18

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/913,684

DATE: 08/30/2001

TIME: 09:34:06

Input Set : A:\ES.txt

Output Set: N:\CRF3\08302001\I913684.raw

L:11 M:270 C: Current Application Number differs, Replaced Application Number

L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date

09/913684
531 Rec'd PCT 16 AUG 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0160
Inventors: Monia and Cowsert
Serial No.: Not yet assigned
Filing Date: Herewith
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: Antisense Modulation of SMAD2 Expression

"Express Mail" Label No. EL 750774529 US
Date of Deposit - August 22 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- (XX) I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: **AUGUST 16** 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

09/915684
 09/12/2001 10 AUG 2001

SEQUENCE LISTING

<110> Brett P. Monia
 Lex M. Cowser
 ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF SMAD2 EXPRESSION

<130> RTSP-0160

<140>

<141>

<150> US 09/255,912

<151> 1999-02-23

<160> 47

<210> 1

<211> 1710

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (107)..(1510)

<400> 1

ccgcggcgcc ggagaagcag ctgccagcc agcagccgc cagccgccgg gaggttcgat 60

acaagaggct gttttcctag cgtggcttgc tgcctttggt aagaac atg tgc tcc 115
 Met Ser Ser
 1

atc ttg cca ttc acg ccg cca gtt gtg aag aga ctg ctg gga tgg aag 163
 Ile Leu Pro Phe Thr Pro Val Val Lys Arg Leu Leu Gly Trp Lys
 5 10 15

aag tca gct ggt ggg tct gga gga gca ggc gga gga gag cag aat ggg 211
 Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu Gln Asn Gly
 20 25 30 35

cag gaa gaa aag tgg tgt gag aaa gca gtg aaa agt ctg gtg aag aag 259
 Gln Glu Glu Lys Trp Cys Glu Lys Ala Val Lys Ser Leu Val Lys Lys
 40 45 50

cta aag aaa aca gga cga tta gat gag ctt gag aaa gcc atc acc act 307
 Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala Ile Thr Thr
 55 60 65

caa aac tgt aat act aaa tgt gtt acc ata cca agc act tgc tct gaa 355
 Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr Cys Ser Glu
 70 75 80

att tgg gga ctg agt aca cca aat acg ata gat cag tgg gat aca aca 403
 Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp Asp Thr Thr
 85 90 95

ggc ctt tac agc ttc tct gaa caa acc agg tct ctt gat ggt cgt ctc 451

Gly	Leu	Tyr	Ser	Phe	Ser	Glu	Gln	Thr	Arg	Ser	Leu	Asp	Gly	Arg	Leu		
100					105					110					115		
cag	gta	tcc	cat	cga	aaa	gga	ttg	cca	cat	gtt	ata	tat	tgc	cga	tta	499	
Gln	Val	Ser	His	Arg	Lys	Gly	Leu	Pro	His	Val	Ile	Tyr	Cys	Arg	Leu		
				120					125					130			
tgg	cgc	tgg	cct	gat	ctt	cac	agt	cat	cat	gaa	ctc	aag	gca	att	gaa	547	
Trp	Arg	Trp	Pro	Asp	Leu	His	Ser	His	His	Glu	Leu	Lys	Ala	Ile	Glu		
			135					140					145				
aac	tgc	gaa	tat	gct	ttt	aat	ctt	aaa	aag	gat	gaa	gta	tgt	gta	aac	595	
Asn	Cys	Glu	Tyr	Ala	Phe	Asn	Leu	Lys	Lys	Asp	Glu	Val	Cys	Val	Asn		
		150					155					160					
cct	tac	cac	tat	cag	aga	gtt	gag	aca	cca	gtt	ttg	cct	cca	gta	tta	643	
Pro	Tyr	His	Tyr	Gln	Arg	Val	Glu	Thr	Pro	Val	Leu	Pro	Pro	Val	Leu		
	165					170				175							
gtg	ccc	cga	cac	acc	gag	atc	cta	aca	gaa	ctt	ccg	cct	ctg	gat	gac	691	
Val	Pro	Arg	His	Thr	Glu	Ile	Leu	Thr	Glu	Leu	Pro	Pro	Leu	Asp	Asp		
	180				185					190					195		
tat	act	cac	tcc	att	cca	gaa	aac	act	aac	ttc	cca	gca	gga	att	gag	739	
Tyr	Thr	His	Ser	Ile	Pro	Glu	Asn	Thr	Asn	Phe	Pro	Ala	Gly	Ile	Glu		
				200					205					210			
cca	cag	agt	aat	tat	att	cca	gaa	acg	cca	cct	cct	gga	tat	atc	agt	787	
Pro	Gln	Ser	Asn	Tyr	Ile	Pro	Glu	Thr	Pro	Pro	Pro	Gly	Tyr	Ile	Ser		
			215					220					225				
gaa	gat	gga	gaa	aca	agt	gac	caa	cag	ttg	aat	caa	agt	atg	gac	aca	835	
Glu	Asp	Gly	Glu	Thr	Ser	Asp	Gln	Gln	Leu	Asn	Gln	Ser	Met	Asp	Thr		
		230					235					240					
ggc	tct	cca	gca	gaa	cta	tct	cct	act	act	ctt	tcc	cct	gtt	aat	cat	883	
Gly	Ser	Pro	Ala	Glu	Leu	Ser	Pro	Thr	Thr	Leu	Ser	Pro	Val	Asn	His		
	245					250					255						
agc	ttg	gat	tta	cag	cca	gtt	act	tac	tca	gaa	cct	gca	ttt	tgg	tgt	931	
Ser	Leu	Asp	Leu	Gln	Pro	Val	Thr	Tyr	Ser	Glu	Pro	Ala	Phe	Trp	Cys		
	260				265					270					275		
tca	ata	gca	tat	tat	gaa	tta	aat	cag	agg	gtt	gga	gaa	acc	ttc	cat	979	
Ser	Ile	Ala	Tyr	Tyr	Glu	Leu	Asn	Gln	Arg	Val	Gly	Glu	Thr	Phe	His		
				280					285					290			
gca	tca	cag	ccc	tca	ctc	act	gta	gat	ggc	ttt	aca	gac	cca	tca	aat	1027	
Ala	Ser	Gln	Pro	Ser	Leu	Thr	Val	Asp	Gly	Phe	Thr	Asp	Pro	Ser	Asn		
			295					300					305				
tca	gag	agg	ttc	tgc	tta	ggc	tta	ctc	tcc	aat	gtt	aac	cga	aat	gcc	1075	
Ser	Glu	Arg	Phe	Cys	Leu	Gly	Leu	Leu	Ser	Asn	Val	Asn	Arg	Asn	Ala		
		310					315					320					
acg	gta	gaa	atg	aca	aga	agg	cat	ata	gga	aga	gga	gtg	cgc	tta	tac	1123	
Thr	Val	Glu	Met	Thr	Arg	Arg	His	Ile	Gly	Arg	Gly	Val	Arg	Leu	Tyr		
		325				330					335						

tac ata ggt ggg gaa gtt ttt gct gag tgc cta agt gat agt gca atc	1171
Tyr Ile Gly Gly Glu Val Phe Ala Glu Cys Leu Ser Asp Ser Ala Ile	
340 345 350 355	
ttt gtg cag agc ccc aat tgt aat cag aga tat ggc tgg cac cct gca	1219
Phe Val Gln Ser Pro Asn Cys Asn Gln Arg Tyr Gly Trp His Pro Ala	
360 365 370	
aca gtg tgt aaa att cca cca ggc tgt aat ctg aag atc ttc aac aac	1267
Thr Val Cys Lys Ile Pro Pro Gly Cys Asn Leu Lys Ile Phe Asn Asn	
375 380 385	
cag gaa ttt gct gct ctt ctg gct cag tct gtt aat cag ggt ttt gaa	1315
Gln Glu Phe Ala Ala Leu Leu Ala Gln Ser Val Asn Gln Gly Phe Glu	
390 395 400	
gcc gtc tat cag cta act aga atg tgc acc ata aga atg agt ttt gtg	1363
Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Ile Arg Met Ser Phe Val	
405 410 415	
aaa ggg tgg gga gca gaa tac cga agg cag acg gta aca agt act cct	1411
Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Thr Val Thr Ser Thr Pro	
420 425 430 435	
tgc tgg att gaa ctt cat ctg aat gga cct cta cag tgg ttg gac aaa	1459
Cys Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp Leu Asp Lys	
440 445 450	
gta tta act cag atg gga tcc cct tca gtg cgt tgc tca agc atg tca	1507
Val Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser Ser Met Ser	
455 460 465	
taa agcttcacca atcaagtcac atgaaaagac ttaatgtaac aactcttctg	1560
tcatagcatt gtgtgtggtc cctatggact gtttactatc caaaagttca agagagaaaa	1620
cagcacttga ggtctcatca attaaagcac cttgtggaat ctgtttccta tatttgaata	1680
ttagatggga aaattagtgt cataaagatc	1710

<210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 2
 ggcttgctgc ctttggttaag

20

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 3

tccatcccag cagtctcttc a

21

<210> 4

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 4

catgtcgtcc atcttgccat tcacg

25

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

gaaggtgaag gtcggagtc

19

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6

gaagatggtg atgggatttc

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7

caagcttccc gttctcagcc

20

<210> 8

<211> 18

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 8
agctgcttct ccgccgcc 18

<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 9
aaacagcctc ttgtatcg 18

<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 10
cgtgaatggc aagatgga 18

<210> 11
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 11
ctcttcacaa ctggcggc 18

<210> 12
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 12
cttccatccc agcagtct 18

<210> 13
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 13
tgctcctcca gacccacc 18

<210> 14
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 14
ctctcctccg catgctcc 18

<210> 15
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 15
ttcctgcccc ttctgctc 18

<210> 16
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 16
ctcacaccac ttttcttc 18

<210> 17
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
tcactgcttt ctcacacc 18

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
cttcaccaga cttttcac 18

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
ctaatacgctcc tgtttttct 18

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
gagtgggtgat ggcttttct 18

<210> 21
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
tattacagtt ttgagtgg 18

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
ggtaacacat ttagtatt 18

<210> 23
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
aagtgccttg tatggtaa 18

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
gagacctggt ttgttcag 18

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
ttcgatggga tacctgga 18

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
tctctgatag tggttaag 18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
ggcaaaactg gtgtctca 18

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
gcggaagtgc tgtagga 18

<210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
ttagtggttt ctggaatg 18

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
gaggtggcgt ttctggaa 18

<210> 31
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
tggtggcac ttgtttct 18

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
gagagcctgt gtccatac 18

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
ggaaagagta gtaggaga

18

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
caggttctga gtaagtaa

18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
gtttctccaa ccctctga

18

<210> 36
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
aaagccatct acagtga

18

<210> 37
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
taaacctaa gagaacct

18

<210> 38
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
taacattgga gagtaaac 18

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
ccttcttgtc atttctac 18

<210> 40
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
aaacttcccc acctatgt 18

<210> 41
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
agattacagc ctggtgga 18

<210> 42
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
ctgagccaga agagcagc 18

<210> 43
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
caccctttca caaaactc 18

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44
actgtagagg tccattca 18

<210> 45
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
aatgctatga cagaagag 18

<210> 46
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 46
gatagtaaac agtccata 18

<210> 47
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 47
acagattcca caaggtgc 18

-1-

ANTISENSE MODULATION OF SMAD2 EXPRESSION**FIELD OF THE INVENTION**

The present invention provides compositions and methods for modulating the expression of Smad2. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding human Smad2. Such oligonucleotides have been shown to modulate the expression of Smad2.

BACKGROUND OF THE INVENTION

The transforming growth factor-beta (TGF- β) superfamily of cytokines regulate a diverse array of physiologic functions including cell proliferation and growth, cell migration, differentiation, development and apoptosis. This large family includes the TGF- β s, activins, and bone-morphogenic proteins (BMPs) and each subgroup initiates a unique signaling cascade activated by ligand-induced serine/threonine kinase receptor complex formation (Wrana, *Miner. Electrolyte Metab.*, 1998, 24, 120-130). These complexes, once formed, recruit and phosphorylate members of a family of cytosolic proteins, known as Smads. Smads exist as monomers in unstimulated cells but homo- or heterodimerize and translocate to the nucleus activating target gene transcription upon ligand binding. Smads, therefore, connect the pathway of TGF- β signaling from the cell membrane to the nucleus.

To date, nine vertebrate Smads have been identified and these have been divided into subgroups based on their functional role in various pathways. Smad1, 5, and MADH6, which is 80% homologous to Smad1, all mediate signal transduction from BMPs while Smad2 and 3 mediate signal transduction from TGF- β s and activins. Collectively, these Smads are known as the pathway-restricted Smads and can form homo or heterodimers. Smad4 has been shown to be a

-2-

shared hetero-oligomerization partner to the pathway-restricted Smads and is known as the common mediator. The last two members of the family, Smad6 and 7, act to inhibit the Smad signaling cascades often by forming unproductive dimers with other Smads and are therefore classified as antagonistic Smads (Heldin et al., *Nature*, 1997, 390, 465-471; Kretzschmar and Massague, *Curr. Opin. Genet. Dev.*, 1998, 8, 103-111).

Smad2 (also known as MADH2, MADR2, hMAD2 and JV18-1) is a member of a subgroup of Smad family transcription factors which are regulated by TGF- β and activins. Upon ligand binding Smad2 becomes phosphorylated and associates with Smad3. This complex then associates with Smad4 and translocates to the nucleus where it effects transcription of target genes. It has been demonstrated that the phosphorylation of Smad2 is necessary for the association with Smad4 (Souchelnytskyi et al., *J. Biol. Chem.*, 1997, 272, 28107-28115) and that Smad2 and Smad4 interact with CREB binding protein, an essential component of the mammalian transcription apparatus (Topper et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1998, 95, 9506-9511).

The Smad2 gene is located on chromosome 18q21, a region that frequently undergoes allelic loss in many cancers. A missense somatic mutation and a 9-bp in-frame deletion were detected in the highly conserved region of JV18-1 among 57 lung cancer specimens taken directly from patients (Uchida et al., *Cancer Res.*, 1996, 56, 5583-5585). In addition, missense and nonsense mutations of the Smad2 gene have also been found in 6-17% of colorectal carcinoma cell lines and primary tumors (Eppert et al., *Cell*, 1996, 86, 543-552).

In normal cells, Smad2 acts to transmit signals from TGF- β and the activins. It has also been shown to mediate cross-talk between receptor tyrosine kinase pathways and

-3-

receptor serine/threonine kinase pathways by acting as a positive effector in the EGF and HGF signaling cascades (de Caestecker et al., *Genes Dev.*, **1998**, 12, 1587-1592).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of Smad2 and to date, strategies aimed at inhibiting Smad2 function have involved the use of dominant-negative mutants of Smad2, gene knock-outs in mice and antisense oligonucleotides designed against Smad2.

Antisense to MADR2 is generally disclosed in WO 98/07849 (Wrana et al.).

Studies of mice lacking the Smad2 gene showed that Smad2 is necessary for embryonic mesoderm formation and the establishment of anterior-posterior polarity (Waldrip et al., *Cell*, **1998**, 92, 797-808). Analysis of mice lacking one copy of the gene found that developmental changes depended on the amount of Smad2 activity and that a defective phenotype was apparent when both of the Smad2 genes are inactivated (Nomura and Li, *Nature*, **1998**, 393, 786-790).

Antisense oligonucleotides designed against Smad2 were used in studies of lung morphogenesis to show that Smad2 negatively regulates lung organogenesis. In these studies, it was demonstrated that treatment of embryonic mouse lung cultures with Smad2 antisense oligonucleotides resulted in increased lung branching morphogenesis (Zhao et al., *Dev. Biol.*, **1998**, 194, 182-195).

In light of the limited strategies available for targeting Smad2 function, there remains a long felt need for additional agents capable of effectively inhibiting Smad2. Therefore, antisense oligonucleotides may provide a promising new pharmaceutical tool for the effective and specific modulation of Smad2 expression.

-4-

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding Smad2, and which modulate the expression of Smad2. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of Smad2 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of Smad2 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Smad2, ultimately modulating the amount of Smad2 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding Smad2. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Smad2" encompass DNA encoding Smad2, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for

-5-

example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA.

5 The overall effect of such interference with target nucleic acid function is modulation of the expression of Smad2. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation
10 of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention,
15 is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an
20 infectious agent. In the present invention, the target is a nucleic acid molecule encoding Smad2. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur
25 such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the
30 gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A
35 minority of genes have a translation initiation codon

-6-

having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Smad2, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted

-7-

effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including

5 nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus

10 including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an

15 mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as

20 "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target

25 regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It

30 has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently

35 complementary to the target, i.e., hybridize sufficiently

-8-

well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick,

5 Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

"Complementary," as used herein, refers to the capacity for

10 precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to

15 each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a

sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable"

20 and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is

25 understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An

antisense compound is specifically hybridizable when

binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or

30 RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of

the antisense compound to non-target sequences under

conditions in which specific binding is desired, i.e.,

under physiological conditions in the case of in vivo

35 assays or therapeutic treatment, and in the case of in

-9-

vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

-10-

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the

-11-

backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

5 Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, 10 phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and 15 those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the 20 preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 25 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do 30 not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside 35 linkages. These include those having morpholino linkages

-12-

(formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching

-13-

of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and
5 oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$
10] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

15 Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and
20 alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{OCH}_3$, $\text{O}(\text{CH}_2)_n\text{NH}_2$, $\text{O}(\text{CH}_2)_n\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{ONH}_2$, and $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_n\text{CH}_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the
25 following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , SOCH_3 , SO_2CH_3 , ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA
30 cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred
35 modification includes 2'-methoxyethoxy ($2'-\text{O}-\text{CH}_2\text{CH}_2\text{OCH}_3$, also

-14-

known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also
5 known as 2'-DMAOE, as described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3'
10 position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents
15 that teach the preparation of such modified sugar structures include, but are not limited to, U.S.:
4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878;
5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811;
5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053;
20 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920,
certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often
25 referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other
30 synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-
35 thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil

-15-

and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl

5 and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No.

10 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S.,

15 Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993.

Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 20 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds.,

25 *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the
30 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;

-16-

5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-

-17-

carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target

-18-

nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well

-19-

known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.:

5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an

-20-

active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE

5 [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to

10 physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are

15 formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are

20 N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a

25 sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms

30 somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an

35 acid form of one of the components of the compositions of

-21-

the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

-22-

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Smad2 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Smad2, enabling sandwich and other assays to easily be constructed to

-23-

exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding Smad2 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Smad2 in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in

-24-

water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium

-25-

carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

15 Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a

-26-

bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion.

Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in

-27-

Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium

-28-

aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated

-29-

hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

5 The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, 10 N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, 15 Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are 20 among the materials that have commonly been administered orally as o/w emulsions.

 In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be 25 defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically 30 microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also

-30-

been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500),

-31-

decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity

-32-

(Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have

-33-

attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As

-34-

the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene

-35-

to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to

-36-

deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S.T.P. Pharma. Sci., 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No.

-37-

5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

5 Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a
10 PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols
15 (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant
20 increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG.
25 Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by
30 Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et

-38-

al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe
5 PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight
10 nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating
15 oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive
20 candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used,
25 e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal
30 composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

-39-

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

-40-

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described

-41-

below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and

-42-

fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have

-43-

the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339).

5 Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

15 Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacycloalkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

25 Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al.,

-44-

PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable

-45-

solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically

-46-

acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

10 Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

-47-

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity

-48-

and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling

-49-

VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2 -displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS)

-50-

protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved

-51-

carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

-52-

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of
5 dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the
10 reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄,
15 filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional
20 was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine
25 (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the
30 addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water
35 layers were back extracted with 200 mL of CHCl₃. The

-53-

combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were
5 evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-
10 acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃,
15 was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored
20 overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl,
25 dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-
30 dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred
35 to a 2 liter stainless steel pressure vessel. MeOH (400

-54-

mL) saturated with NH_3 gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl_3 (700 mL) and extracted with saturated NaHCO_3 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were combined, dried over MgSO_4 and concentrated. The residue

-55-

obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

5 2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside
10 amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine
15 and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500
20 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient
25 temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was
30 dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl

-56-

ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

-57-

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine

5'-O-tert-Butylidiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under

-58-

vacuum; residue chromatographed to get 5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-tert-Butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

-59-

2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol)

-60-

was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was
5 dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam
10 (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are
15 prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]
20

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor
25 amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J.,
30 WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide

-61-

2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-
5'-O-(4,4'-dimethoxytrityl)guanosine. As before the
hydroxyl group may be displaced by N-hydroxyphthalimide via
a Mitsunobu reaction, and the protected nucleoside may
5 phosphitylated as usual to yield 2-N-isobutyryl-6-O-
diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-
dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-
diisopropylphosphoramidite].

Example 2**10 Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O)
oligonucleotides are synthesized on an automated DNA
synthesizer (Applied Biosystems model 380B) using standard
phosphoramidite chemistry with oxidation by iodine.

15 Phosphorothioates (P=S) are synthesized as for the
phosphodiester oligonucleotides except the standard
oxidation bottle was replaced by 0.2 M solution of 3H-1,2-
benzodithiole-3-one 1,1-dioxide in acetonitrile for the
stepwise thiation of the phosphite linkages. The thiation
20 wait step was increased to 68 sec and was followed by the
capping step. After cleavage from the CPG column and
deblocking in concentrated ammonium hydroxide at 55°C (18
h), the oligonucleotides were purified by precipitating
twice with 2.5 volumes of ethanol from a 0.5 M NaCl

25 solution. Phosphinate oligonucleotides are prepared as
described in U.S. Patent 5,508,270, herein incorporated by
reference.

Alkyl phosphonate oligonucleotides are prepared as
described in U.S. Patent 4,469,863, herein incorporated by
30 reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are
prepared as described in U.S. Patents 5,610,289 or
5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as
35 described in U.S. Patent, 5,256,775 or U.S. Patent

-62-

5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4**PNA Synthesis**

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5**Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s

-64-

repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1

ammonia/ethanol at room temperature overnight then

5 lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is
10 then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

15 [2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-

(Methoxyethyl)] Chimeric Phosphorothioate

Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were
20 prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy

Phosphorothioate]--[2'-O-(2-Methoxyethyl)

25 Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with
30 the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage

-65-

Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage

-66-

Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ).

5 Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature
10 (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

15 **Example 8**

Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual
20 products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds
25 utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

30 **Example 9**

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at
35 measurable levels. This can be routinely determined using,

-67-

for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used.

5 T-24 cells:

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

-68-

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

Example 10

Analysis of oligonucleotide inhibition of Smad2 expression

Antisense modulation of Smad2 expression can be assayed in a variety of ways known in the art. For example, Smad2 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can

-69-

be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the art.

Smad2 protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Smad2 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can

-70-

be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and
5 can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11**Poly(A)+ mRNA isolation**

10 Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons,
15 Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the
20 plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10
25 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C
30 hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

-71-

Example 12**Total RNA Isolation**

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

Example 13**Real-time Quantitative PCR Analysis of Smad2 mRNA Levels**

Quantitation of Smad2 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of

-72-

polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM

-73-

MgCl₂, 300 μM each of dATP, dCTP and dGTP, 600 μM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μL poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). Smad2 probes and primers were designed to hybridize to the human Smad2 sequence, using published sequence information (GenBank accession number AF027964, incorporated herein as SEQ ID NO:1).

For Smad2 the PCR primers were:
forward primer: GGCTTGCTGCCTTTGGTAAG (SEQ ID NO: 2)
reverse primer: TCCATCCCAGCAGTCTCTTCA (SEQ ID NO: 3) and the PCR probe was: FAM-CATGTCGTCCATCTTGCCATTTCACG-TAMRA (SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

For GAPDH the PCR primers were:
forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 5)
reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO: 6) and the PCR probe was: 5' JOE-CAAGCTTCCC GTTCTCAGCC- TAMRA 3' (SEQ ID NO: 7) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of Smad2 mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAzol™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated

-74-

by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA).

Membranes were probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions with a Smad2 specific probe prepared by PCR using the forward primer GGCTTGCTGCCTTTGGTAAG (SEQ ID NO: 2) and the reverse primer TCCATCCCAGCAGTCTCTTCA (SEQ ID NO: 3). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of Smad2 expression- phosphorothioate oligodeoxynucleotides

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human Smad2 RNA, using published sequences (GenBank accession number AF027964, incorporated herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF027964), to which the oligonucleotide binds. All compounds in Table 1 are oligodeoxynucleotides with phosphorothioate backbones

-75-

(internucleoside linkages) throughout. The compounds were analyzed for effect on Smad2 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of Smad2 mRNA levels by phosphorothioate oligodeoxynucleotides

	ISIS#	REGION	TARGET	SEQUENCE	%	SEQ ID
			SITE		Inhibition	NO.
10	27737	5' UTR	5	agctgcttctccgccgcc	73	8
	27738	5' UTR	57	aaacagcctcttgtatcg	71	9
	27739	Coding	113	cgtgaatggcaagatgga	53	10
	27740	Coding	130	ctcttcacaaactggcggc	84	11
15	27741	Coding	146	cttccatcccagcagtct	90	12
	27742	Coding	173	tgctcctccagaccacc	99	13
	27743	Coding	185	ctctcctccgcctgctcc	99	14
	27744	Coding	200	ttcctgcccattctgctc	92	15
	27745	Coding	215	ctcacaccacttttcttc	90	16
20	27746	Coding	225	tcactgctttctcacacc	92	17
	27747	Coding	239	cttcaccagacttttcac	85	18
	27748	Coding	264	ctaatacgctcctgttttct	67	19
	27749	Coding	291	gagtggatgatggctttct	60	20
	27750	Coding	303	tattacagttttgagtgg	48	21
25	27751	Coding	317	ggtaacacatttagtatt	52	22
	27752	Coding	330	aagtgccttggtatggtaa	57	23
	27753	Coding	420	gagacctggtttggtcag	54	24
	27754	Coding	450	ttcgatgggatacctgga	1	25
	27755	Coding	596	tctctgatagtggtaagg	51	26
30	27756	Coding	616	ggcaaaactggtgtctca	74	27
	27757	Coding	663	gcggaagtctctgtagga	57	28
	27758	Coding	703	ttagtgttttctggaatg	52	29
	27759	Coding	756	gaggtggcgtttctggaa	71	30
	27760	Coding	796	tggttggtcacttgtttct	42	31
35	27761	Coding	825	gagagcctgtgtccatac	71	32
	27762	Coding	854	ggaaagagtagtaggaga	52	33
	27763	Coding	903	caggttctgagtaagtaa	46	34
	27764	Coding	955	gtttctccaaccctctga	80	35
	27765	Coding	995	aaagccatctacagtgag	66	36
40	27766	Coding	1034	taaacctaaagcagaacct	63	37
	27767	Coding	1047	taacattggagagtaaac	46	38

-76-

27768	Coding	1079	ccttcttgtcatttctac	43	39
27769	Coding	1125	aaacttccccacctatgt	82	40
27770	Coding	1234	agattacagcctggtgga	43	41
27771	Coding	1277	ctgagccagaagagcagc	82	42
5 27772	Coding	1354	cacccttttcacaaaactc	85	43
27773	Coding	1431	actgtagaggtccattca	58	44
27774	3' UTR	1553	aatgctatgacagaagag	24	45
27775	3' UTR	1583	gatagtaaacagtccata	50	46
27776	3' UTR	1647	acagattccacaaggtgc	78	47

As shown in Table 1, SEQ ID NOs 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46 and 47 demonstrated at least 40% inhibition of Smad2 expression in this assay and are therefore preferred.

Example 16:

Antisense inhibition of Smad2 expression- phosphorothioate 2'-MOE gapmer oligonucleotides

In accordance with the present invention, a second series of oligonucleotides targeted to human Smad2 were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF027964), to which the oligonucleotide binds.

All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines.

-77-

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments. If present, "N.D." indicates "no data".

5

Table 2

Inhibition of Smad2 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS#	REGION	TARGET	SEQUENCE	%	SEQ ID
			SITE		Inhibition	NO.
10	27777	5' UTR	5	agctgcttctccgccgcc	76	8
	27778	5' UTR	57	aaacagcctcttgatcg	66	9
	27779	Coding	113	cgtgaatggcaagatgga	87	10
	27780	Coding	130	ctcttcacaactggcggc	82	11
15	27781	Coding	146	cttccatcccagcagtc	74	12
	27782	Coding	173	tgtcctccagaccacc	95	13
	27783	Coding	185	ctctcctccgctgctcc	87	14
	27784	Coding	200	ttectgcccattctgctc	91	15
	27785	Coding	215	ctcacaccacttttcttc	83	16
20	27786	Coding	225	tcaactgctttctcacacc	94	17
	27787	Coding	239	cttcaccagacttttcac	83	18
	27788	Coding	264	ctaactcgtcctgttttct	82	19
	27789	Coding	291	gagtggatgatggctttct	75	20
	27790	Coding	303	tattacagttttgagtgg	71	21
25	27791	Coding	317	ggtaaacacatttagtatt	74	22
	27792	Coding	330	aagtgcttggtatggtaa	59	23
	27793	Coding	420	gagacctggtttgttcag	71	24
	27794	Coding	450	ttcgatgggatacctgga	85	25
	27795	Coding	596	tctctgatagtggtaagg	61	26
30	27796	Coding	616	ggcaaaactggtgtctca	94	27
	27797	Coding	663	gcggaagtctctgtagga	91	28
	27798	Coding	703	ttagtgttttctggaatg	57	29
	27799	Coding	756	gaggtggcgtttctggaa	76	30
	27800	Coding	796	tggtggtcacttgtttct	64	31
35	27801	Coding	825	gagagcctgtgtccatac	89	32
	27802	Coding	854	ggaaagagtagtaggaga	72	33
	27803	Coding	903	caggttctgagtaagtaa	78	34
	27804	Coding	955	gtttctccaaccctctga	82	35
	27805	Coding	995	aaagccatctacagtga	85	36
40	27806	Coding	1034	taaacctaaagcagaacct	76	37
	27807	Coding	1047	taacattggagagtaa	55	38

-78-

	27808	Coding	1079	ccttcttggtcatttctac	67	39
	27809	Coding	1125	aaacttccccacctatgt	85	40
	27810	Coding	1234	agattacagcctggtgga	66	41
	27811	Coding	1277	ctgagccagaagagcagc	68	42
5	27812	Coding	1354	caccctttcacaaaactc	72	43
	27813	Coding	1431	actgtagaggtccattca	62	44
	27814	3' UTR	1553	aatgctatgacagaagag	41	45
	27815	3' UTR	1583	gatagtaaacagtccata	68	46
10	27816	3' UTR	1647	acagattccacaaggtgc	81	47

As shown in Table 2, SEQ ID NOS 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46 and 47 demonstrated at least 50% inhibition of Smad2 expression in this experiment and are therefore preferred.

Example 17

Western blot analysis of Smad2 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Smad2 is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-79-

What is claimed is:

1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding human Smad2, wherein said antisense compound inhibits the expression of human Smad2.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46 or 47.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46 or 47.

5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

-80-

11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a
5 colloidal dispersion system.

14. The composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Smad2 in human cells or tissues comprising contacting said cells or
10 tissues with the antisense compound of claim 1 so that expression of Smad2 is inhibited.

16. A method of treating a human having a disease or condition associated with Smad2 comprising administering to said animal a therapeutically or prophylactically effective
15 amount of the antisense compound of claim 1 so that expression of Smad2 is inhibited.

17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder or a lung developmental disorder.

20 18. The method of claim 17 wherein the hyperproliferative disorder is cancer.

19. The antisense compound of claim 1 which is targeted to a mutated form of Smad2.

Docket No.
RTSP-0160

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Antisense Modulation of Smad2 Expression

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 11 January 2000 as United States Application No. or PCT International

Application Number PCT/US99/00654

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/255,912

February 23, 1999

Patented

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



Herb Boswell, Reg. No. 27,311
 Laurel Spear Bernstein, Reg. No. 37,280
 Robert S. Andrews, Reg. No. 44,508
 April Logan, Reg. no. 33,950
 Neil S. Bartfeld, Reg. No. 39,901
 Kenneth H. Tarbet, Reg. No. 43,181
 Donna T. Ward, Reg. No. P48,271
 of the firm
 ISIS Pharmaceuticals, Inc. -Carlsbad Research Center
 2292 Faraday Avenue
 Carlsbad, California 92008

Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)
 Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor Brett P. Monia	
Sole or first inventor's signature <i>Brett P. Monia</i>	Date 8/16/01
Residence Encinitas, California	
Citizenship US	
Post Office Address 2306 Casa Hermosa Court	
Encinitas, California 92024	

Full name of second inventor, if any Lex M. Cowser	
Second inventor's signature <i>Lex M. Cowser</i>	Date 8/16/01
Residence San Mateo, California	
Citizenship US	
Post Office Address 1299 Parrott Drive	
San Mateo, California 94402	

SEQUENCE LISTING

<110> Brett P. Monia
Lex M. Cowser
ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF SMAD2 EXPRESSION

<130> RTSP-0044

<150> US 09/255,912

<151> 1999-02-23

<160> 47

<210> 1

<211> 1710

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (107)..(1510)

<400> 1

ccgcggcggc ggagaagcag ctgccagcc agcagccgc cagccgcgg gaggttcgat 60

acaagaggct gttttcctag cgtggcttgc tgcctttggt aagaac atg tgc tcc 115
Met Ser Ser
1

atc ttg cca ttc acg ccg cca gtt gtg aag aga ctg ctg gga tgg aag 163
Ile Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu Gly Trp Lys
5 10 15

aag tca gct ggt ggg tct gga gga gca ggc gga gga gag cag aat ggg 211
Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu Gln Asn Gly
20 25 30 35

cag gaa gaa aag tgg tgt gag aaa gca gtg aaa agt ctg gtg aag aag 259
Gln Glu Glu Lys Trp Cys Glu Lys Ala Val Lys Ser Leu Val Lys Lys
40 45 50

cta aag aaa aca gga cga tta gat gag ctt gag aaa gcc atc acc act 307
Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala Ile Thr Thr
55 60 65

caa aac tgt aat act aaa tgt gtt acc ata cca agc act tgc tct gaa 355
Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr Cys Ser Glu
70 75 80

att tgg gga ctg agt aca cca aat acg ata gat cag tgg gat aca aca 403
Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp Asp Thr Thr
85 90 95

ggc ctt tac agc ttc tct gaa caa acc agg tct ctt gat ggt cgt ctc 451
Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp Gly Arg Leu
100 105 110 115

cag gta tcc cat cga aaa gga ttg cca cat gtt ata tat tgc cga tta 499
 Gln Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr Cys Arg Leu
 120 125 130

tgg cgc tgg cct gat ctt cac agt cat cat gaa ctc aag gca att gaa 547
 Trp Arg Trp Pro Asp Leu His Ser His His Glu Leu Lys Ala Ile Glu
 135 140 145

aac tgc gaa tat gct ttt aat ctt aaa aag gat gaa gta tgt gta aac 595
 Asn Cys Glu Tyr Ala Phe Asn Leu Lys Lys Asp Glu Val Cys Val Asn
 150 155 160

cct tac cac tat cag aga gtt gag aca cca gtt ttg cct cca gta tta 643
 Pro Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro Pro Val Leu
 165 170 175

gtg ccc cga cac acc gag atc cta aca gaa ctt ccg cct ctg gat gac 691
 Val Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro Leu Asp Asp
 180 185 190 195

tat act cac tcc att cca gaa aac act aac ttc cca gca gga att gag 739
 Tyr Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala Gly Ile Glu
 200 205 210

cca cag agt aat tat att cca gaa acg cca cct cct gga tat atc agt 787
 Pro Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly Tyr Ile Ser
 215 220 225

gaa gat gga gaa aca agt gac caa cag ttg aat caa agt atg gac aca 835
 Glu Asp Gly Glu Thr Ser Asp Gln Gln Leu Asn Gln Ser Met Asp Thr
 230 235 240

ggc tct cca gca gaa cta tct cct act act ctt tcc cct gtt aat cat 883
 Gly Ser Pro Ala Glu Leu Ser Pro Thr Thr Leu Ser Pro Val Asn His
 245 250 255

agc ttg gat tta cag cca gtt act tac tca gaa cct gca ttt tgg tgt 931
 Ser Leu Asp Leu Gln Pro Val Thr Tyr Ser Glu Pro Ala Phe Trp Cys
 260 265 270 275

tca ata gca tat tat gaa tta aat cag agg gtt gga gaa acc ttc cat 979
 Ser Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Val Gly Glu Thr Phe His
 280 285 290

gca tca cag ccc tca ctc act gta gat ggc ttt aca gac cca tca aat 1027
 Ala Ser Gln Pro Ser Leu Thr Val Asp Gly Phe Thr Asp Pro Ser Asn
 295 300 305

tca gag agg ttc tgc tta ggt tta ctc tcc aat gtt aac cga aat gcc 1075
 Ser Glu Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn Arg Asn Ala
 310 315 320

acg gta gaa atg aca aga agg cat ata gga aga gga gtg cgc tta tac 1123
 Thr Val Glu Met Thr Arg Arg His Ile Gly Arg Gly Val Arg Leu Tyr
 325 330 335

tac ata ggt ggg gaa gtt ttt gct gag tgc cta agt gat agt gca atc 1171
 Tyr Ile Gly Gly Glu Val Phe Ala Glu Cys Leu Ser Asp Ser Ala Ile
 340 345 350 355

ttt gtg cag agc ccc aat tgt aat cag aga tat ggc tgg cac cct gca 1219
 Phe Val Gln Ser Pro Asn Cys Asn Gln Arg Tyr Gly Trp His Pro Ala
 360 365 370
 aca gtg tgt aaa att cca cca ggc tgt aat ctg aag atc ttc aac aac 1267
 Thr Val Cys Lys Ile Pro Pro Gly Cys Asn Leu Lys Ile Phe Asn Asn
 375 380 385
 cag gaa ttt gct gct ctt ctg gct cag tct gtt aat cag ggt ttt gaa 1315
 Gln Glu Phe Ala Ala Leu Leu Ala Gln Ser Val Asn Gln Gly Phe Glu
 390 395 400
 gcc gtc tat cag cta act aga atg tgc acc ata aga atg agt ttt gtg 1363
 Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Ile Arg Met Ser Phe Val
 405 410 415
 aaa ggg tgg gga gca gaa tac cga agg cag acg gta aca agt act cct 1411
 Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Thr Val Thr Ser Thr Pro
 420 425 430 435
 tgc tgg att gaa ctt cat ctg aat gga cct cta cag tgg ttg gac aaa 1459
 Cys Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp Leu Asp Lys
 440 445 450
 gta tta act cag atg gga tcc cct tca gtg cgt tgc tca agc atg tca 1507
 Val Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser Ser Met Ser
 455 460 465
 taa agcttcacca atcaagtccc atgaaaagac ttaatgtaac aactcttctg 1560
 tcatagcatt gtgtgtgggc cctatggact gtttactatc caaaagttca agagagaaaa 1620
 cagcacttga ggtctcatca attaaagcac cttgtggaat ctgtttccta tatttgaata 1680
 ttagatggga aaattagtgt cataaagatc 1710

<210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 2
 ggcttgctgc ctttggttaag 20

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 3
 tccatcccag cagtctcttc a 21

<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence

<223> PCR Probe

<400> 4
catgtcgtcc atcttgccat tcacg

25

<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 5
gaaggtgaag gtcggagtc

19

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 6
gaagatggtg atgggatttc

20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<223> PCR Probe

<400> 7
caagcttccc gttctcagcc

20

<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 8
agctgcttct ccgccgcc

18

<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9

aaacagcctc ttgtatcg

18

<210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10

cgtgaatggc aagatgga

18

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 11

ctcttcacaa ctggcggc

18

<210> 12

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12

cttccatccc agcagtct

18

<210> 13

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 13

tgctcctcca gacccacc

18

<210> 14

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 14

ctctcctcgg cctgctcc

18

<210> 15
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 15
ttcctgcca ttctgctc 18

<210> 16
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 16
ctcacaccac ttttcttc 18

<210> 17
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17
tcactgcttt ctcacacc 18

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18
cttcaccaga cttttcac 18

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
ctaactgtcc tgttttct 18

<210> 20
<211> 18
<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20

gagtggatgat ggctttct

18

<210> 21

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21

tattacagtt ttgagtgg

18

<210> 22

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22

ggtaacacat ttagtatt

18

<210> 23

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

aagtgcttgg tatggtaa

18

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

gagacctggt ttgttcag

18

<210> 25

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25
ttcgatggga tacctgga 18

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26
tctctgatag tggtaagg 18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27
ggcaaaactg gtgtctca 18

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28
gcggaagtgc tgtagga 18

<210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29
ttagtggttt ctggaatg 18

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30
gaggtggcgt ttctggaa 18

<210> 31
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31
tgttggtcac ttgtttct 18

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32
gagagcctgt gtccatac 18

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33
ggaaagagta gtaggaga 18

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34
caggttctga gtaagtaa 18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35
gtttctccaa ccctctga 18

<210> 36
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36

aaagccatct acagtgag

18

<210> 37

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37

taaacctaac cagaacct

18

<210> 38

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38

taacattgga gagtaaac

18

<210> 39

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39

ccttcttgtc atttctac

18

<210> 40

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40

aaacttcccc acctatgt

18

<210> 41

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41

agattacagc ctggtgga

18

<210> 42
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42
ctgagccaga agagcagc 18

<210> 43
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
caccctttca caaaactc 18

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
actgtagagg tccattca 18

<210> 45
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
aatgctatga cagaagag 18

<210> 46
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
gatagtaaac agtccata 18

<210> 47
<211> 18
<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47

acagattcca caaggtgc

18